Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (131-140 of 239) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancerAngeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
American Journal of Obstetrics and Gynecology|July 25, 2025
Advancing physician-scientist career development in obstetrics and gynecology: 40 years of the American Association of Obstetricians and Gynecologists Foundation scholar programAngeles Alvarez Secord, William H Catherino, Jessie Paradis, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Gynecologic Oncology|August 11, 2007
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancerAngeles Alvarez Secord, Laura J Havrilesky, Victoria Bae-Jump, et al.
BMC Cancer|May 28, 2010
Expression signatures of TP53 mutations in serous ovarian cancersMarcus Q Bernardini, Tsukasa Baba, Paula S Lee, et al.
Gynecologic Oncology|April 17, 2013
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancerMicael Lopez-Acevedo, Laura J Havrilesky, Gloria Broadwater, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 15, 2020
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancerJulia Rose Salinaro, Kourtnie McQuillen, Megan Stemple, et al.
Gynecologic Oncology|May 7, 2020
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapiesBradley J Monk, Robert L Coleman, Kathleen N Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group studyRaymond J Osborne, Virginia Filiaci, Julian C Schink, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Pageof 24

Showing results (131-140 of 239) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancerAngeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
American Journal of Obstetrics and Gynecology|July 25, 2025
Advancing physician-scientist career development in obstetrics and gynecology: 40 years of the American Association of Obstetricians and Gynecologists Foundation scholar programAngeles Alvarez Secord, William H Catherino, Jessie Paradis, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Gynecologic Oncology|August 11, 2007
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancerAngeles Alvarez Secord, Laura J Havrilesky, Victoria Bae-Jump, et al.
BMC Cancer|May 28, 2010
Expression signatures of TP53 mutations in serous ovarian cancersMarcus Q Bernardini, Tsukasa Baba, Paula S Lee, et al.
Gynecologic Oncology|April 17, 2013
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancerMicael Lopez-Acevedo, Laura J Havrilesky, Gloria Broadwater, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 15, 2020
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancerJulia Rose Salinaro, Kourtnie McQuillen, Megan Stemple, et al.
Gynecologic Oncology|May 7, 2020
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapiesBradley J Monk, Robert L Coleman, Kathleen N Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group studyRaymond J Osborne, Virginia Filiaci, Julian C Schink, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Pageof 24